Recombinant Human TrkA/NTRK1 Protein (His & Fc Tag)(Active) | PKSH031280

(No reviews yet) Write a Review
SKU:
575-PKSH031280
€998.00
Frequently bought together:

Description

Recombinant Human TrkA/NTRK1 Protein (His & Fc Tag)(Active) | PKSH031280 | Gentaur US, UK & Europe Disrtribition

Synonyms: MTC;p140-TrkA;TRK;Trk-A;TRK1;TRKA

Active Protein: Active protein

Activity: A DNA sequence encoding the human NTRK1 (NP_002520.2) extracellular domain (Met 1-Pro 382) was fused with the C-terminal polyhistidine-tagged Fc region of human IgG1 at the C-terminus.

Protein Construction: A DNA sequence encoding the human NTRK1 (NP_002520.2) extracellular domain (Met 1-Pro 382) was fused with the C-terminal polyhistidine-tagged Fc region of human IgG1 at the C-terminus.

Fusion Tag: C-His & Fc

Species: Human

Expressed Host: HEK293 Cells

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Purity: > 98 % as determined by reducing SDS-PAGE.

Endotoxin: < 1.0 EU per µg as determined by the LAL method.

Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Molecular Mass: 66 kDa

Formulation: Lyophilized from sterile PBS, pH 7.4

Reconstitution: Please refer to the printed manual for detailed information.

Background: TRKA is a member of the neurotrophic tyrosine kinase receptor (NTKR) family. It is a membrane-bound receptor that, upon neurotrophin binding, phosphorylates itself and members of the MAPK pathway. Isoform TrkA-III promotes angiogenesis and has oncogenic activity when overexpressed. Isoform TrkA-I is found in most non-neuronal tissues. Isoform TrkA-II is primarily expressed in neuronal cells. TrkA-III is specifically expressed by pluripotent neural stem and neural crest progenitors. The presence of NTRK1 leads to cell differentiation and may play a role in specifying sensory neuron subtypes. Mutations in TRKA gene have been associated with congenital insensitivity to pain, anhidrosis, self-mutilating behavior, mental retardation and cancer. It was originally identified as an oncogene as it is commonly mutated in cancers, particularly colon and thyroid carcinomas. TRKA is required for high-affinity binding to nerve growth factor (NGF), neurotrophin-3 and neurotrophin-4/5 but not brain-derived neurotrophic factor (BDNF). Known substrates for the Trk receptors are SHC1, PI 3-kinase, and PLC-gamma-1. NTRK1 has a crucial role in the development and function of the nociceptive reception system as well as establishment of thermal regulation via sweating. It also activates ERK1 by either SHC1- or PLC-gamma-1-dependent signaling pathway. Defects in NTRK1 are a cause of congenital insensitivity to pain with anhidrosis and thyroid papillary carcinoma.Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

Research Area: Neuroscience, Cancer, metabolism

View AllClose